Loading…
20/20 Biolabs, Inc. is projected to decline to $0.5259 by 2027, a -11% move from its current price of $0.5891. AIDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.5484 | $0.5891 | $0.6329 | +0.01% |
| Jul 13 | $0.5324 | $0.5892 | $0.652 | +0.01% |
| Jul 14 | $0.5205 | $0.5892 | $0.667 | +0.02% |
| Jul 15 | $0.5106 | $0.5892 | $0.68 | +0.02% |
| Jul 16 | $0.5021 | $0.5893 | $0.6916 | +0.03% |
| Jul 17 | $0.4945 | $0.5893 | $0.7023 | +0.03% |
| Jul 18 | $0.4876 | $0.5893 | $0.7122 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4876 | $0.5893 | $0.7122 | +0.04% |
| Week 2 | $0.451 | $0.5895 | $0.7707 | +0.07% |
| Week 3 | $0.4248 | $0.5898 | $0.8188 | +0.11% |
| Week 4 | $0.4039 | $0.59 | $0.8618 | +0.15% |
| Week 5 | $0.3864 | $0.5902 | $0.9015 | +0.19% |
| Week 6 | $0.3712 | $0.5904 | $0.9391 | +0.22% |
| Week 7 | $0.3578 | $0.5906 | $0.975 | +0.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED, and OneTest for Longevity, which measures inflammatory biomarkers.
The company also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was incorporated in 2000 and is based in Gaithersburg, Maryland. It was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025.
AIDX currently trades at $0.615 per share and has a market capitalization of $7.53M. The stock ranks 5055 by market cap and sits in a small-cap segment with a lightweight public float.
The 30-day technical picture is NEUTRAL, with RSI14 at 30 and a SMA50 of $1.07. The 30-day range runs from $0.3562 to $1.06, with support at $0.55 and resistance at $1.29. Annualized volatility is 200%, underscoring high price movement potential.
The year-by-year forecast outlines a broad set of outcomes, including periods of bearish risk in the late 2020s and a path toward bullish momentum in the 2030s and beyond, with notable upside projected in 2040 and 2050 states.
A major floor 58.7% below — a decisive break under it would weaken the trend.
The nearest floor, 6.6% below — buyers have tended to step in here.
The nearest ceiling, 74.8% above — a clean break opens room to run.
A major ceiling 467.0% above — clearing it would confirm fresh momentum.
Key AIDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AIDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.592 | Sell | $0.59 | Sell |
| MA 10 | $0.594 | Sell | $0.6019 | Sell |
| MA 20 | $0.6315 | Sell | $0.6669 | Sell |
| MA 50 | $0.9672 | Sell | $1.43 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.01 | Neutral |
| Stoch RSI (14) | 86.83 | Sell |
| CCI (20) | -46.58 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -6.35 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | -2.27 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 55.19 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 0.58 | Buy |
| ADX (14) | 42.69 | Sell |
| ATR (14) | 0.04 | Info |
The near-term picture remains neutral, with momentum not clearly favoring a breakout or a breakdown. RSI14 sits at 30, indicating room to move before becoming oversold, while price action trades below the $1.07 SMA50 barrier.
The 30-day range spans $0.3562 to $1.06, showing a wide swing potential in the period ahead. Support is noted near $0.55 while resistance sits around $1.29, offering a defined but susceptible trading band. The asset exhibits high volatility, with annualized volatility at 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.55 | $0.5891 | $0.8558 | 0% | Neutral | |
| $0.3435 | $0.5259 | $0.8707 | -11% | Neutral | |
| $0.3471 | $0.5894 | $1.06 | 0% | Neutral | |
| $0.2511 | $0.4674 | $0.8979 | -21% | Bearish | |
| $0.2223 | $0.4515 | $0.9136 | -23% | Bearish | |
| $0.2812 | $0.6219 | $1.32 | +6% | Neutral | |
| $0.3206 | $0.7124 | $1.57 | +21% | Bullish | |
| $0.3491 | $0.7759 | $1.77 | +32% | Bullish | |
| $0.3219 | $0.7154 | $1.65 | +21% | Bullish | |
| $0.2816 | $0.6259 | $1.44 | +6% | Neutral | |
| $0.468 | $1.04 | $2.39 | +77% | Bullish | |
| $0.5351 | $1.19 | $2.73 | +102% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.55 | $0.5891 | $0.7768 | +0.00% |
| August 2026 | $0.5012 | $0.6243 | $0.82 | +5.97% |
| September 2026 | $0.465 | $0.592 | $0.801 | -5.18% |
| October 2026 | $0.4601 | $0.5969 | $0.8277 | +0.83% |
| November 2026 | $0.4691 | $0.6186 | $0.8754 | +3.63% |
| December 2026 | $0.4434 | $0.5937 | $0.8558 | -4.02% |
Click any year to see its month-by-month AIDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AIDX to range from $0.55 to $0.8558 through 2026. The $0.5891 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The AIDX price prediction for 2027 points to an average of $0.5259 (low $0.3435, high $0.8707) — a potential decline of -11% on today's $0.5891. Price action looks broadly range-bound.
In 2028, AIDX is projected to trade between $0.3471 and $1.06, averaging $0.5894 — a potential gain of 0% from today's $0.5891. That is up +12% on the projected 2027 average. A consolidation phase looks the most probable path here.
20/20 Biolabs, Inc.'s 2029 outlook centres on $0.4674, within a $0.2511 to $0.8979 range. That is -21% versus the projected 2028 average. That marks a -21% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2030, AIDX could reach as high as $0.9136, with a base case around $0.4515 and support toward $0.2223 — roughly -23% from $0.5891. Expect choppier, lower action through this leg of the cycle.
Expect AIDX to range from $0.2812 to $1.32 through 2031. The $0.6219 average target implies a +6% move from current prices. That is up +38% on the projected 2030 average. Price action looks broadly range-bound.
The AIDX price prediction for 2032 points to an average of $0.7124 (low $0.3206, high $1.57) — a potential gain of +21% on today's $0.5891. Buyers look set to stay in control over this stretch.
In 2033, AIDX is projected to trade between $0.3491 and $1.77, averaging $0.7759 — a potential gain of +32% from today's $0.5891. That is up +9% on the projected 2032 average. Momentum favours further upside here.
20/20 Biolabs, Inc.'s 2034 outlook centres on $0.7154, within a $0.3219 to $1.65 range. That is -8% versus the projected 2033 average. That marks a +21% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, AIDX could reach as high as $1.44, with a base case around $0.6259 and support toward $0.2816 — roughly +6% from $0.5891. Price action looks broadly range-bound.
Expect AIDX to range from $0.468 to $2.39 through 2040. The $1.04 average target implies a +77% move from current prices. That is up +66% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The AIDX price prediction for 2050 points to an average of $1.19 (low $0.5351, high $2.73) — a potential gain of +102% on today's $0.5891. Momentum favours further upside here.
Investing $1,000 in AIDX today (≈ 1,697.504668 AIDX) could be worth
$2,018.4
+$1,018.4 (+102%) by 2050 · US Dollar
Based on the average projected AIDX price of $1.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AIDXwould be worth at today's price.
$1,000 invested in AIDX on Feb 19, 2026 (≈ 41.928721 AIDX) would be worth
$24.7
-$975.3 (-97.5%) today · 0.02× · US Dollar
Based on a AIDX entry price of $23.85 vs. today's $0.5891.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.62 | $950.16 | -5.0% |
| 1 month ago | $0.87 | $677.13 | -32.3% |
| 3 months ago | $1.88 | $313.35 | -68.7% |
| All time ago | $23.85 | $24.7 | -97.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AIDX forecast.
$1.20 is within our bullish range by 2031, but above the base case.
Implied market cap at $1.20: $14.7M
The multi-year forecast maps a varied path with a transition from bearish conditions in the late 2020s to bullish momentum into the 2030s and beyond. The 2026 average price is $0.615 with a min of $0.55 and a max of $0.883 (sentiment NEUTRAL), while 2027 shows a decline to an average of $0.5557 with min $0.3621 and max $0.9221 (ROI -9.6, NEUTRAL).
In 2028 the average is $0.6195 (min $0.3641, max $1.12) with ROI 0.7 and NEUTRAL sentiment, followed by 2029 at an average of $0.4757 (min $0.255, max $0.9149) with ROI -22.7 and BEARISH sentiment. 2030 repeats the same average with a min of $0.2337 and max of $0.9636, ROI -22.6 and BEARISH sentiment. The turns toward steadier growth occur in 2031-2034, moving from neutral to bullish: 2031 average $0.6618, max $1.40 (ROI 7.6, NEUTRAL); 2032 average $0.7363, max $1.62 (ROI 19.7, NEUTRAL); 2033 average $0.8139, max $1.85 (ROI 32.3, BULLISH); 2034 average $0.7495, max $1.72 (ROI 21.9, BULLISH).
Longer-term upside strengthens in 2040 with average $1.09 and max $2.51 (ROI 77.2, BULLISH), and again in 2050 with average $1.22 and max $2.81 (ROI 98.3, BULLISH). These are estimates, not guarantees, and outcomes depend on a range of market factors beyond the data presented here.
Tap a question to reveal the answer.
The forecast for 2030 shows min $0.2337, avg $0.4757, max $0.9636 with ROI -22.6 and sentiment BEARISH.
Forecasts show a mix of signals: NEUTRAL in 2026-2028, BEARISH in 2029-2030, NEUTRAL in 2031-2032, then BULLISH in 2033-2034 and again in 2040 and 2050, with max ROI reaching 98.3% in 2050. These are estimates and not guarantees.
Yes. The max values in the forecast exceed $1 in multiple years: 2031 max $1.40; 2032 max $1.62; 2033 max $1.85; 2034 max $1.72; 2040 max $2.51; 2050 max $2.81.
Current price is $0.615 and the market capitalization is $7.53M, with a rank of 5055.
Sentiment is NEUTRAL; RSI14 is 30; SMA50 is $1.07. The 30-day range is $0.3562 to $1.06, with support at $0.55 and resistance at $1.29; annualized volatility is 200%.
20/20 Biolabs, Inc. Community Discussion
0Share your 20/20 Biolabs, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.